Overview
Alimentiv runs clinical trials for pharmaceutical and biotechnology companies developing treatments for gastrointestinal diseases. Its contract research services cover study design, site monitoring and regulatory submissions, with medical imaging used to measure how patients respond to treatment. The company combines central image reading with tissue analysis and biomarker testing through sister laboratory AcelaBio. Sponsors pay for trial execution, scientific consulting and statistical services that support drug development from early studies through regulatory review. Founded in 1986, Alimentiv is headquartered in London, Ontario, and operates internationally.
Work here?Claim your company
Simplify's take
What believers are saying
- Research leadership extends beyond trial execution: Alimentiv's leaders design investigator-initiated studies including REACT and VERDICT.
- Portugal full-time employees become Alimentiv Trust beneficiaries after one year; permanent membership follows five employment years.
- Alimentiv schedules a December holiday shutdown: availability and benefits details vary by country and role.
What critics are saying
- Alimentiv's Portugal monitoring role requires approximately 40-60% travel, depending on project requirements and geography.
- Alimentiv advertises temporary employment: its on-site London, Ontario Administrative Generalist contract lasts one year.
- AcelaBio's AI has diagnostic limits: its eosinophil and lymphocyte models remain in development, restricted to research use.
What makes Alimentiv unique
- Alimentiv builds shared research tools: its freely available Robarts Histopathology Index measures ulcerative colitis tissue inflammation.
- AcelaBio stretches scarce biopsy material: histopathology, immunostaining and spatial biology assays use the same tissue block.
- Alimentiv reports broad trial penetration: it supports over 70% of inflammatory bowel disease compounds in development.
Help us improve and share your feedback! Did you find this helpful?